Jubilant Pharmova Limited (NSE:JUBLPHARMA)
India
· Delayed Price · Currency is INR 1,126.40
+32.20 (2.94%)
Jun 16, 2025, 3:29 PM IST
Jubilant Pharmova Revenue
In the fiscal year ending March 31, 2025, Jubilant Pharmova had annual revenue of 72.35B INR with 7.93% growth. Jubilant Pharmova had revenue of 19.29B in the quarter ending March 31, 2025, with 9.68% growth.
Revenue
72.35B
Revenue Growth
+7.93%
P/S Ratio
2.46
Revenue / Employee
13.40M
Employees
5,399
Market Cap
178.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 72.35B | 5.32B | 7.93% |
| Mar 31, 2024 | 67.03B | 4.21B | 6.71% |
| Mar 31, 2023 | 62.82B | 1.52B | 2.47% |
| Mar 31, 2022 | 61.30B | 316.29M | 0.52% |
| Mar 31, 2021 | 60.99B | 1.23B | 2.05% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 271.45B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 122.07B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Alkem Laboratories | 129.65B |
Jubilant Pharmova News
- 6 months ago - Jubilant to buy 40% in Coke bottler's parent for 10k cr - The Times of India
- 7 months ago - Bernstein maintains Outperform rating on Jubilant Foodworks, highlights three pillars to achieve $10 billion market cap - Business Upturn
- 7 months ago - Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer - Benzinga
- 7 months ago - CLSA maintains ‘Underperform’ rating on Jubilant FoodWorks with target price of Rs 445, expecting 26% downside - Business Upturn
- 7 months ago - Jefferies maintains ‘Buy’ rating on Jubilant FoodWorks with target price of Rs 880, expecting 46% upside - Business Upturn
- 7 months ago - Morgan Stanley maintains ‘Equal-weight’ rating on Jubilant FoodWorks with target price of Rs 620 - Business Upturn
- 9 months ago - Stocks to Watch: RIL, Adani Enterprises, BEL, GAIL, Kaynes Technology, Lupin, Jubilant Pharma, Zomato and morein focus today (Sept 30, 2024) - Business Upturn